Newsletter | January 14, 2016

01.14.16 -- What Biosimilar Makers Need To Know About 2016

Biosimilar Development
 
Featured Editorial
What Biosimilar Makers Need To Know About 2016
By Anna Rose Welch, Editor, Biosimilar Development   By Anna Rose Welch, Editor, Biosimilar Development
Over the past few weeks, I've been reading predictions of what pharma is going to look like in 2016. Here are a few of the key developments and trends that are going to be especially important for those building a business around biosimilars to keep in mind.
Could Birth Of "Big Generic" Be Foreshadowing "Big Biosimilar?"
By Anna Rose Welch, Editor, Biosimilar Development   By Anna Rose Welch, Editor, Biosimilar Development
In 2015 the generics market saw several players jump ship and one company grow significantly — and to some, alarmingly — larger. If buyers are consolidating and causing generics companies to consolidate, isn’t it natural to expect a similar trend to hit the biosimilars market when it’s more established?
Implications Of Biosimilars In 2016
By PwC's Health Research Institute   By PwC’s Health Research Institute
Finally entering the U.S. market, biosimilar drugs have the potential to be as disruptive as generic drugs following the Hatch-Waxman Act of 1984. The first U.S. biosimilar — Sandoz’s Zarxio, which prevents infections in cancer patients — received FDA approval in 2015 and entered the market at a 15 percent discount. At least four biosimilar applications are pending FDA review in 2016, with another 50 in the FDA review process.
Wireless Dose-Compliance Monitoring In Drug-Delivery Devices
By Phillips-Medisize   By Phillips-Medisize
Incorporating wireless technology into medical devices is about more than just keeping up with the hottest technology trends; the benefits are real and significant, especially with regard to monitoring and encouraging dose compliance in the pharmaceutical and medical realm.
News Headlines
Momenta Pharmaceuticals Announces Worldwide Collaboration With Mylan To Jointly Develop And Commercialize Six Biosimilar Products
Newly Presented Data From The Largest Real-World Study To Date Demonstrates Effectiveness Of Biosimilar Infliximab In Patients With Inflammatory Bowel Diseases Who Have Been Switched From Reference Infliximab
Japan Seeks To Become Active Player In Biosimilar Market By 2020
Connect With Biosimilar Development:
Twitter